Tools
Selective Serotonin Reuptake Inhibitor Toxicity
Introduction
Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed antidepressants. Other clinical indications for SSRI use include anxiety disorders, obsessive-compulsive disorder, panic disorders, and eating disorders. Compared to their predecessors, the monoamine oxidase inhibitors and tricyclic antidepressants, SSRIs are associated with fewer toxic effects.[1]
Individual SSRIs differ from each other regarding structure and pharmacokinetics but, as a group, they act by potentiating the action of serotonin. SSRIs are less cardiotoxic than many first-generation antidepressants, but there is still evidence that they inhibit sodium, calcium, and potassium ion channels at concentrations near therapeutic levels.[2] Citalopram and escitalopram are known to cause QTc prolongation.[3][4] There also have been reports of atrial fibrillation and bradycardia related to fluoxetine use.[5]
Adverse effects of SSRIs are vague and nonspecific but include hyponatremia, anorgasmia, sedation, stimulation, and gastric irritation.[6][7] Seizures are uncommon but have been reported; Isbister et al.[8] reported a seizure incidence of 1.9%. They may also inhibit platelet secretion, aggregation, and plug formation.[9]
Patients with adverse effects from SSRIs will present with a range of symptoms, and some researchers have advocated for the term “serotonin toxicity” rather than “serotonin syndrome” to highlight that this condition is a spectrum of symptoms rather than a single clinical entity. [10][11] In patients with mild symptoms, the benefit they receive from the prescribed SSRI may outweigh the negative side effects.
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Serotonin toxicity is the most serious drug reaction from inadvertent or intentional SSRI overdose and can be iatrogenic, caused by the introduction of a serotonergic agent, increased dosing of an established serotonergic agent or after coadministration with another agent that increases serotonin activity.[12] The most severe cases are caused by combinations of drugs that enhance serotonin levels by acting through separate mechanisms, for example, a monoamine oxidase inhibitor and a serotonin reuptake inhibitor.[13]
Many medications affect serotonin levels by different overlapping mechanisms. In addition to SSRIs, ondansetron, methadone, clomipramine, amitriptyline, dextromethorphan, fentanyl, meperidine, tramadol, trazodone, venlafaxine, and pentazocine increase serotonin levels by blocking reuptake. Medications that can increase serotonin levels by inhibiting serotonin metabolism include linezolid, methylene blue, St. John's wort, or monoamine oxidase inhibitors like phenelzine, selegiline, and isocarboxazid. Methylenedioxymethamphetamine (MDMA) and mirtazapine enhance serotonin release. Tryptophan is a serotonin precursor. Cocaine increases serotonin synthesis. Buspirone, fentanyl, dihydroergotamine, lithium, lysergic acid diethylamide (LSD), metoclopramide and triptans stimulate serotonin receptors.[12][14][15][16] Research is still ongoing on the subject of opioid safety with concomitant SSRI.[17][18][19]Studies have shown that synthetic opioids can inhibit SERT (serotonin transporter) but fentanyl and oxycodone, which have not shown inhibitory effects on SERT, have been reported anecdotally in cases of serotonin toxicity.[20][21]
Epidemiology
The American Association of Poison Control Centers reported over 50,000 overdose cases in 2016 where SSRIs were mentioned; of these reported cases, 102 were fatal, but in all but one of these fatalities co-ingestants were involved.[22] Sertraline and fluoxetine were the SSRIs most commonly taken in excess.[22] One study analyzing 469 SSRI overdoses reported serotonin toxicity in 14% of cases.[8]
History and Physical
Serotonin toxicity is a clinical diagnosis initially defined by the Sternbach criteria. Generally, these symptoms include neuromuscular excitation, autonomic stimulation and altered level of consciousness. The presence of generalized clonus indicates serotonin toxicity.[13] Neuromuscular symptoms are usually more prominent in the lower extremities.[15]
Due to the nonspecific nature of the Sternbach criteria, the Hunt serotonin toxicity criteria were developed. The Hunt serotonin toxicity criteria decision rule describes 5 constellations of symptoms that define serotonin toxicity[10]:
- Spontaneous clonus
- Inducible clonus and agitation or diaphoresis
- Ocular clonus with agitation or diaphoresis
- Tremor and hyperreflexia
- Ocular clonus, hypertonicity, and temperature greater than 38 C
Besides signs and symptoms, a history suggestive of serotonin exposure or overdose is required to diagnose serotonin toxicity.
Minor symptoms of serotonin toxicity include vomiting, somnolence, mydriasis, or diaphoresis. Someone can see severe symptoms (decreased level of consciousness, ECG changes, and seizures with overdoses greater than 75 times the recommended daily dose.[23] The concentration of the different serotonin receptors is highest in the neuromuscular, autonomic nervous, and gastrointestinal (GI) systems, accounting for the variety of common adverse effects of serotonin excess.[14]
Evaluation
Initial evaluation and treatment of a patient with serotonin toxicity are similar to any overdose, altered mental status, or poisoning patient with the establishment of intravenous access, initiation of cardiac monitoring, stabilization of vital signs, and fluid resuscitation. Diagnosis of serotonin toxicity is not only clinical but also a diagnosis of exclusion, therefore, even though diagnosis does not rely on any specific laboratory value, thorough testing to rule out other causes of altered mental status is essential.[12]
Treatment / Management
Nelson et al.[24] established guidelines for out-of-hospital management of isolated SSRI overdose and recommended at-home observation of patients who were experiencing minor symptoms and had ingested less than 5 times their own prescribed dose or less than 5 times the initial adult dose in an SSRI-naive patient. This should only be done in close conjunction with a regional poison control center.(A1)
Treatment is largely supportive and involves discontinuation of all serotonergic therapies, control of agitation with benzodiazepines and defervescence.[25][12] Droperidol and haloperidol should not be used to control agitation as these medications can worsen hyperthermia by inhibiting sweating through their anticholinergic properties.[26](B3)
In severe cases of serotonin toxicity where patients required endotracheal intubation and ventilatory support, hypertonicity, rigidity, and high-grade fever were evident.[12]
Muscular rigidity is thought to be the primary cause of hyperthermia and death so patients with severe symptoms should be rapidly cooled. If benzodiazepines do not sufficiently control muscle spasm or temperature is greater than 41.1 C, intubation with neuromuscular blockade and paralysis can be considered.[12] In cases refractory to supportive care, cyproheptadine or chlorpromazine, which have anti-serotonergic properties, can be administered; although, it is unclear if these medications alter patient outcome.[27][28] Cyproheptadine does not have an IV formulation and must, therefore, be administered via a nasogastric or orogastric tube.[29] There is no role for acetaminophen, NSAIDs, or aspirin in control of hyperthermia as the increased temperature is not caused by a change in the hypothalamic temperature set point.[27](B3)
Differential Diagnosis
Serotonin toxicity should not be confused with the neuroleptic malignant syndrome (NMS) which usually has an insidious onset of bradykinesia, "lead pipe" rigidity and other extrapyramidal symptoms.[13] Duration of NMS is on the order of weeks, significantly longer than serotonin toxicity, which usually resolves within 24 hours of discontinuation of serotonergic therapies [29]
Prognosis
Prognosis is good, and full recovery is expected.[29] The median length of stay for these SSRI overdose admissions was 15.3 hours in one study.[8] Mild cases can be observed in the emergency department for at least 6 hours before being discharged safely home.[12] Pharmacokinetics of the specific drug involved appear to affect duration; fluoxetine has a longer half-life than other SSRIs at 4 to 6 days.[7][29]
Patients with severe symptoms should be dispositioned to the intensive care unit.
Enhancing Healthcare Team Outcomes
SSRIs are prescribed by many healthcare workers including the primary care provider, psychiatrist, pain specialist, and the nurse practitioner. Unlike their predecessors, the monoamine oxidase inhibitors and tricyclic antidepressants, SSRIs are much safer in overdose.[1] However, at the same time SSRIs are also associated with several serious adverse effects that need close monitoring. All clinicians who prescribe these drugs should educate the patient on the potential adverse effects. Nursing staff can also counsel the patients, monitor treatment effectiveness, watch for adverse drug reactions, and alert the prescriber regarding any issues that arise. In addition, the pharmacist has to make sure that the patient is not on any other medication that may lead to a drug-drug interaction with the SSRI. More important the pharmacist should ensure that multiple clinicians do not prescribe similar agents leading to polypharmacy and report concerns to the clinical team. An interprofessional approach between clinicians and pharmacists working together will result in the best outcomes. [Level 5]
Clear, closed-loop communication between pre-hospital, regional poison control center, emergency department, and intensive care staff is essential to make sure that patients prescribed SSRI receive the appropriate level of care while safely allocating resources.[30]
References
McKenzie MS, McFarland BH. Trends in antidepressant overdoses. Pharmacoepidemiology and drug safety. 2007 May:16(5):513-23 [PubMed PMID: 17200994]
Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Current pharmaceutical design. 2004:10(20):2463-75 [PubMed PMID: 15320756]
Level 3 (low-level) evidenceHasnain M, Howland RH, Vieweg WV. Escitalopram and QTc prolongation. Journal of psychiatry & neuroscience : JPN. 2013 Jul:38(4):E11. doi: 10.1503/jpn.130055. Epub [PubMed PMID: 23791140]
Level 3 (low-level) evidenceVieweg WV,Hasnain M,Howland RH,Hettema JM,Kogut C,Wood MA,Pandurangi AK, Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? The American journal of medicine. 2012 Sep [PubMed PMID: 22748401]
Level 3 (low-level) evidencePacher P, Ungvari Z, Kecskemeti V, Furst S. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. Current medicinal chemistry. 1998 Oct:5(5):381-90 [PubMed PMID: 9756980]
Level 3 (low-level) evidenceVarela Piñón M, Adán-Manes J. Selective Serotonin Reuptake Inhibitor-Induced Hyponatremia: Clinical Implications and Therapeutic Alternatives. Clinical neuropharmacology. 2017 Jul/Aug:40(4):177-179. doi: 10.1097/WNF.0000000000000221. Epub [PubMed PMID: 28622213]
Marken PA, Munro JS. Selecting a Selective Serotonin Reuptake Inhibitor: Clinically Important Distinguishing Features. Primary care companion to the Journal of clinical psychiatry. 2000 Dec:2(6):205-210 [PubMed PMID: 15014630]
Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. Journal of toxicology. Clinical toxicology. 2004:42(3):277-85 [PubMed PMID: 15362595]
Level 2 (mid-level) evidenceHalperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues in clinical neuroscience. 2007:9(1):47-59 [PubMed PMID: 17506225]
Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM : monthly journal of the Association of Physicians. 2003 Sep:96(9):635-42 [PubMed PMID: 12925718]
Level 2 (mid-level) evidenceGillman PK. Serotonin syndrome: history and risk. Fundamental & clinical pharmacology. 1998:12(5):482-91 [PubMed PMID: 9794145]
Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. The Ochsner journal. 2013 Winter:13(4):533-40 [PubMed PMID: 24358002]
Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. The Medical journal of Australia. 2007 Sep 17:187(6):361-5 [PubMed PMID: 17874986]
Frank C. Recognition and treatment of serotonin syndrome. Canadian family physician Medecin de famille canadien. 2008 Jul:54(7):988-92 [PubMed PMID: 18625822]
Level 3 (low-level) evidenceFoong AL,Grindrod KA,Patel T,Kellar J, Demystifying serotonin syndrome (or {i}serotonin toxicity{/i}). Canadian family physician Medecin de famille canadien. 2018 Oct [PubMed PMID: 30315014]
Bartlett D. Drug-Induced Serotonin Syndrome. Critical care nurse. 2017 Feb:37(1):49-54. doi: 10.4037/ccn2017169. Epub [PubMed PMID: 28148614]
Sundaramurthy S, Annamalai B, Samuvel DJ, Shippenberg TS, Jayanthi LD, Ramamoorthy S. Modulation of serotonin transporter function by kappa-opioid receptor ligands. Neuropharmacology. 2017 Feb:113(Pt A):281-292. doi: 10.1016/j.neuropharm.2016.10.011. Epub 2016 Oct 12 [PubMed PMID: 27743931]
Barann M, Stamer UM, Lyutenska M, Stüber F, Bönisch H, Urban B. Effects of opioids on human serotonin transporters. Naunyn-Schmiedeberg's archives of pharmacology. 2015 Jan:388(1):43-9. doi: 10.1007/s00210-014-1056-3. Epub 2014 Oct 22 [PubMed PMID: 25332055]
Rickli A, Liakoni E, Hoener MC, Liechti ME. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. British journal of pharmacology. 2018 Feb:175(3):532-543. doi: 10.1111/bph.14105. Epub 2018 Jan 6 [PubMed PMID: 29210063]
Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British journal of anaesthesia. 2005 Oct:95(4):434-41 [PubMed PMID: 16051647]
Baldo BA. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Archives of toxicology. 2018 Aug:92(8):2457-2473. doi: 10.1007/s00204-018-2244-6. Epub 2018 Jun 18 [PubMed PMID: 29916050]
Level 3 (low-level) evidenceGummin DD, Mowry JB, Spyker DA, Brooks DE, Fraser MO, Banner W. 2016 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 34th Annual Report. Clinical toxicology (Philadelphia, Pa.). 2017 Dec:55(10):1072-1252. doi: 10.1080/15563650.2017.1388087. Epub 2017 Nov 29 [PubMed PMID: 29185815]
Barbey JT, Roose SP. SSRI safety in overdose. The Journal of clinical psychiatry. 1998:59 Suppl 15():42-8 [PubMed PMID: 9786310]
Nelson LS, Erdman AR, Booze LL, Cobaugh DJ, Chyka PA, Woolf AD, Scharman EJ, Wax PM, Manoguerra AS, Christianson G, Caravati EM, Troutman WG. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clinical toxicology (Philadelphia, Pa.). 2007 May:45(4):315-32 [PubMed PMID: 17486478]
Level 1 (high-level) evidenceNisijima K, Shioda K, Yoshino T, Takano K, Kato S. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochemistry international. 2003 Jul:43(2):155-64 [PubMed PMID: 12620284]
Level 3 (low-level) evidenceTanii H, Taniguchi N, Niigawa H, Hosono T, Ikura Y, Sakamoto S, Kudo T, Nishimura T, Takeda M. Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level. Brain research. 1996 Dec 16:743(1-2):263-70 [PubMed PMID: 9017254]
Level 3 (low-level) evidenceEyer F, Zilker T. Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity. Critical care (London, England). 2007:11(6):236 [PubMed PMID: 18096088]
Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. The Journal of emergency medicine. 1998 Jul-Aug:16(4):615-9 [PubMed PMID: 9696181]
Level 3 (low-level) evidenceBirmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2003 May 27:168(11):1439-42 [PubMed PMID: 12771076]
Level 3 (low-level) evidenceStoner SC,Marken PA,Watson WA,Switzer JL,Barber MF,Meyer VL,Sommi RW Jr,Steele MT, Antidepressant overdoses and resultant emergency department services: the impact of SSRIs. Psychopharmacology bulletin. 1997 [PubMed PMID: 9493477]